Activation of the contact system in patients with a first acute myocardial infarction

Joke Konings*, Jose W. P. Govers-Riemslag, Henri M. H. Spronk, Johannes L. Waltenberger, Hugo ten Cate

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Web of Science)

Abstract

Introduction: The contribution of the contact system to arterial thrombosis is unclear, results of clinical studies are conflicting. Particularly, little is known about the involvement of the contact system in the progression of arterial thrombosis. Therefore, we investigated the activation of the contact system during an acute myocardial infarction (AMI) and 3 and 6 months following the acute event. Methods: Plasma of patients with a first AMI was collected on admission and 3 and 6 months after the AMI. The levels of complexes of activated factor XI (FXIa), FXIIa and kallikrein with C1 esterase inhibitor (C1INH) and the levels of complexes of FXIa with alpha(1)-antitrypsin (AT) were measured in these plasmas. Recurrent cardiovascular events were recorded during a one year period after the AMI. Results: We observed that the levels of FXIa-C1INH were elevated during the acute phase compared to the steady-phase 3 and 6 months after the AMI. The levels of FXIa-AT, FXIIa-C1INH and kallikrein-C1INH did not change over time. The levels of FXIa-C1INH, FXIa-AT, FXIIa-C1INH and kallikrein-C1INH were not predictive for a recurrent event. Conclusion: We observed that during an AMI, the activation of FXI was increased. The levels of FXIIa-C1INH were not elevated, suggesting that activation of FXI during the acute phase did not result from contact activation. The levels of the enzyme inhibitor complexes were not predictive for a recurrent event one year after the first AMI.
Original languageEnglish
Pages (from-to)138-142
JournalThrombosis Research
Volume132
Issue number1
DOIs
Publication statusPublished - Jul 2013

Keywords

  • Acute myocardial infarction
  • Coagulation factor XI
  • Contact system
  • Coagulation factor XII
  • Prekallikrein
  • C1 esterase inhibitor

Cite this